Review article: Treatment of Helicobacter pylori infection and factors influencing eradication

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 16, Issue 1, 2002, Pages 24-30

  Qasim, A ^a   O'Morain, C A ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; BISMUTH SALICYLATE; BISMUTH SALT; CLARITHROMYCIN; HELICOBACTER PYLORI VACCINE; METRONIDAZOLE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; TETRACYCLINE; ANTIBIOTIC AGENT; AZITHROMYCIN; BISMUTH; ESOMEPRAZOLE; FURAZOLIDONE; LANSOPRAZOLE; NITROFURANTOIN; NITROIMIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE; RANITIDINE BISMUTH CITRATE; RIFABUTIN; RIFAMYCIN DERIVATIVE; TINIDAZOLE; PROTON PUMP;

ANTIBIOTIC RESISTANCE; ATROPHIC GASTRITIS; CANCER SURGERY; CLINICAL TRIAL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; DUODENUM ULCER; ERADICATION THERAPY; HELICOBACTER INFECTION; HUMAN; META ANALYSIS; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; STOMACH ULCER; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; ANTIBIOTIC SENSITIVITY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; MARGINAL ZONE LYMPHOMA; MEDICAL SPECIALIST; META ANALYSIS (TOPIC); NONHUMAN; PATHOGEN CLEARANCE; DRUG ANTAGONISM; DRUG COMBINATION; HELICOBACTER PYLORI;

DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PROTON PUMPS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 1342313826     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. de Boer WA. Topics in Helicobacter pylori infection: focus on a 'search-and-treat' strategy for ulcer disease. Scand J Gastroenterol 2000; 232(Suppl.): 4-9.
2. Malfertheiner et al. Current Concepts in the Management of Helicobacter pylori Infection. The Maastricht Consensus Report 2-2000. Aliment Pharmacol Ther 2002; 16: 167-180.
3. Pilotto A, Franceschi M, DiMario F. Helicobacter pylori-associated peptic ulcer disease in elderly patients. Clin Geriatrics 2000; 8: 49-58.
4. Veldhuyzen van Zanten SJO, Bradette M, Farley A, et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther 1999; 13: 289-95.
5. Malfertheiner P, Bayerdorffer E, Diete U, et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 1999; 13: 703-12.
6. Damman HG, Folsch UR, Hahn EG, et al. Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration. Helicobacter 2000; 5: 41-51.
7. Pilotto A, Leandro G, Franceschi M, et al. The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. Aliment Pharmacol Ther 1999; 13: 667-73.
8. Pilotto A, Franceschi M, Leandro G, et al. Efficacy of 7-day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients. J Gastroenterol Hepatol 1999; 14: 468-75.
9. Miwa H, Yamada T, Sato K, et al. Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole. Dig Dis Sci 2000; 45: 77-82.
10. Lee JM, Deasy E, O'Morain CA. Helicobacter pylori eradication therapy: a discrepancy between current guidelines and clinical practice. Eur J Gastroenterol Hepatol 2000; 12: 433-7.
11. Labenz J, Malfertheiner P. [Helicobacter pylori-when and how do gastroenterologists treat themselves? A clinical and practical survey]. Dtsch Med Wochenschr 1997; 133: 637-42.
12. Fallone CA, Loo V, Joseph L, Barkun J, Kostyk R, Barkun AN. Predictors of failure of Helicobacter pylori eradication and predictors of ulcer resurgence: a randomized controlled trial. Clin Invest Med 1999; 22: 185-94.
13. Geogopoulos SD, Ladas SD, Karatapanis S, et al. Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole, amoxicillin and clarithromycin. Dig Dis Sci 2000; 45: 63-7.
14. Kearney DJ, Brousal A. Treatment of Helicobacter pylori infection in clinical practice in the United States: results from 224 patients. Dig Dis Sci 2000; 45: 265-71.
15. Lee M, Kemp JA, Canning A, Enag C, Tataronis G, Farraye FA. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch Intern Med 1999; 159: 2312-6.
16. Sakura K, Takahashi H, Yamaguchi Y, et al. [Importance of drug selection and the use of sensitivity tests in the eradication therapy for Helicobacter pylori]. Nippon Rinsho 1999; 57: 72-5.
17. Murakami K, Satoh R, Okimoto T, Kagawa J, Fujioka T, Kodama M. [Selection of antibiotics and planning of eradication for H. pylori infection]. Nippon Rinsho 2001; 59: 308-13.
18. Peitz U, Hackelsberger A, Malfertheiner P. A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy. Drugs 1999; 57: 905-20.
19. Calvet X, Garcia N, Campo R, Brullet E, Comet R, Navarro M. Two-day quadruple therapy for cure of Helicobacter pylori infection: a comparative, randomized trial. Am J Gastroenterol 1998; 93: 932-4.
20. Catalano F, Branciforte G, Catanzaro R, Cipolla R, Bentivegna C, Brogna A. Helicobacter pylori-positive duodenal ulcer: three-day antibiotic eradication regimen. Aliment Pharmacol Ther 2000; 14: 1329-34.
21. Calabrese C, Di Febo G, Areni A, Scialpi C, Biasco G, Miglioli M. Pantoprazole, azithromycin and tinidazole: short duration triple therapy for eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 1613-7.
22. Wong BC, Wang WH, Wong WM, et al. Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study. Aliment Pharmacol Ther 2001; 15: 843-50.
23. Hurenkamp GJ, Van Der Ende A, Grundmeijer HG, Tytgat GN, Van Der Hulst RW. Equally high efficacy of 4, 7 and 10-day triple therapies to eradicate Helicobacter pylori infection in patients with ulcer diseases. Aliment Pharmacol Ther 2000; 14: 1065-70.
24. O'Connor HJ, McLouchlin R, Kelly S, Laundon J, Cunnane K. Lansoprazole triple therapy for Helicobacter pylori-is 5 days enough? Aliment Pharmacol Ther 1998; 12: 273-6.
25. Neville PM, Everett S, Langworthy H, et al. The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. Aliment Pharmacol Ther 1999; 13: 497-501.
26. Catalano F, Catanzaro R, Branciforte G, et al. Five-day triple therapy in Helicobacter pylori-positive duodenal ulcer: an eighteen-month follow-up. J Clin Gastroenterol 2000; 31: 130-6.
27. Isomoto H, Furusu H, Morikawa T, et al. 5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 1619-23.
28. Cammarota G, Cannizzaro O, Ojetti V, et al. Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxicillin or tinidazole for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 73-7.
29. Nagahara A, Miwa H, Yamada T, Kurosawa A, Ohkura R, Sato N. Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. Aliment Pharmacol Ther 2001; 15: 417-21.
30. Gisbert JP, Marcos S, Gisbert JL, Pajares JM. High efficacy of ranitidine bismuth citrate, amoxicillin, clarithromycin and metronidazole twice daily for only five days in Helicobacter pylori eradication. Helicobacter 2001; 6: 157-62.
31. Ellenrieder V, Boeck W, Richter C, Marre R, Adler G, Glasbrenner B. Prevalence of resistance to clarithromycin and its clinical importance on the efficacy of Helicobacter pylori eradication. Scand J Gastroenterol 1999; 34: 750-6.
32. Avidan B, Melzer E, Keller N, Bar-Meir S. The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication. Isr Med Assoc J 2001; 3: 163-5.
33. Inoue K, Satoh K, Muto H, Sugano K. [Antimicrobial resistant test of H. pylori]. Nippon Rinsho 2001; 59: 291-5.
34. Kalach N, Benhamou PH, Campeotto F, Bergeret M, Dupont C, Raymond J. Clarithromycin resistance and eradication of Helicobacter pylori in children. Antimicrob Agents Chemother 2001; 45: 2134-5.
35. Toracchio S, Cellini L, Di Camli E, et al. Role of antibiotic susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 639-43.
36. Penta JA, Fox JG, Ferraro MJ, Versalovic J. Molecular resistance testing of Helicobacter pylori in gastric biopsies. Arch Pathol Lab Med 2001; 125: 493-7.
37. Owen RJ, Ferrus M, Gibson J. Amplified fragment length polymorphism genotyping of metronidazole-resistant Helicobacter pylori infecting dyspeptics in England. Clin Microbiol Infect 2001; 7: 244-53.
38. Wong BC, Wang WH, Berg DE, et al. High prevalence of mixed infections by Helicobacter pylori in Hong Kong: metronidazole sensitivity and overall genotype. Aliment Pharmacol Ther 2001; 15: 493-503.
39. Pilotto A, Franceschi M, Rassu M, et al. Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study. Dig Liver Dis 2000; 32: 667-72.
40. Xiao SD, Liu WZ, Hu PJ, et al. A multicentre study on eradication of Helicobacter pylori using four 1-week triple therapies in China. Aliment Pharmacol Ther 2001; 15: 81-6.
41. Huang AH, Sheu BS, Yang HB, Huang CC, Wu JJ, Lin XZ. Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy. J Formos Med Assoc 2000; 99: 704-9.
42. Wang WH, Wong BC, Lam SK. Pooled analysis of Helicobacter pylori eradication regimens in Asia. J Gastroenterol Hepatol 2000; 15: 1007-17.
43. Lind T, Megraud F, Unge P, et al. The MACH2 Study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999; 116: 248-53.
44. Maconi G, Parente F, Russo A, Vago L, Imbesi V, Porro GB. Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? Am J Gastroenterol 2001; 96: 359-66.
45. Danese S, Armuzzi A, Romano A, et al. Efficacy and tolerability of antibiotics in patients undergoing H. pylori eradication. Hepatogastroenterology 2001; 48: 465-7.
46. Huang JQ, Hunt RH. Review: eradication of Helicobacter pylori. Problems and recommendations. J Gastroenterol Hepatol 1997; 12: 590-8.
47. Gisbert JP, Gisbert JL, Marcos S, Garcia Gravalos R, Carpio D, Pajares JM. Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole. Aliment Pharmacol Ther 1999; 13: 1311-6.
48. Huang IQ, Hunt RH. Treatment after failure: the problem of 'non-responders.' Gut 1999; 45(Suppl. 1): 140-4.
49. Tzivras M, Balatsos V, Souyioultzis S, Tsirantonaki M, Skandali N, Archimandritis A. High eradication rate of Helicobacter pylori using a four-drug regimen in patients previously treated unsuccessfully. Clin Ther 1997; 19: 906-12.
50. Sheu BS, Wu JJ, Yang HB, Huang AH, Lin XZ. One-week proton pump inhibitor-based triple therapy eradicates residual Helicobacter pylori after failed dual therapy. J Formos Med Assoc 1998; 97: 266-70.
51. Bock H, Koop H, Lehn N, Heep M. Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience. J Clin Gastroenterol 2000; 31: 222-5.
52. Perri F, Festa V, Clemente R, Quitadamo M, Andriulli A. Rifabutin-based 'rescue therapy' for Helicobacter infection in patients after failure of standard regimens. Aliment Pharmacol Ther 2000; 14: 311-6.
53. Zullo A, Hassan C, Campo SM, et al. A triple therapy regimen after failed Helicobacter pylori treatments. Aliment Pharmacol Ther 2001; 15: 1193-7.
54. Perri F, Festa V, Clemente R, et al. Randomized study of two 'rescue' therapies for Helicobacter pylori-infected patients after failure of standard triple therapy. Am J Gastroenterol 2001; 96: 58-62.
55. Perri F, Villani MR, Quitadamo M, Annese V, Niro GA, Andriulli A. Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy? Aliment Pharmacol Ther 2001; 15: 1017-22.
56. Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis of the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001; 36: 690-700.
57. Seppala K, Kosunen TU, Nuutinen H, et al. Cure of Helicobacter pylori infection after failed primary treatment: one-center results from 120 patients. Scand J Gastroenterol 2001; 35: 929-34.
58. Gasbarrini A, Ojetti V, Armuzzi A, et al. Efficacy of a multistep strategy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 79-83.
59. Heep M, Rieger U, Beck D, Lehn N. Mutation in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000; 44: 1075-7.
60. Verdu EF, Armstrong D, Idstrom JP, et al. Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis. Scand J Gastroenterol 1996; 31: 1151-6.
61. Labenz J, Beker JA, Dekker CP, Farley A, Klor HU, Jonsson A. Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxicillin increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients. Aliment Pharmacol Ther 1997; 11: 515-22.
62. Furuta T, Shirai N, Takashima M, et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001; 69: 158-68.
63. Sakai T, Aoyama N, Kita T, et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 2001; 18: 721-7.
64. Pantoflickova D, Dorta G, Jornod P, Ravic M, Blum AL. Identification of the characteristics influencing the degree of antisecretory activity of PPI's. Gastroenterology 2000; 118: 5895A (Abstract).
65. Wang J, Tauchi Y, Deguchi Y, Morioto K, Tabata Y, Ikada Y. Positively charged gelatin microspheres as gastric mucoadhesive drug delivery system for eradication of H. pylori. Drug Deliv 2000; 7: 237-43.
66. Shah S, Qaqish R, Patel V, Amiji M. Evaluation of the factors influencing stomach-specific delivery of antibacterial agents for Helicobacter pylori infection. J Pharm Pharmacol 1999; 51: 667-72.